116 related articles for article (PubMed ID: 36124827)
1. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease.
Chrysavgis L; Giannakodimos I; Chatzigeorgiou A; Tziomalos K; Papatheodoridis G; Cholongitas E
Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):835-849. PubMed ID: 36124827
[TBL] [Abstract][Full Text] [Related]
2. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
3. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development.
Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y
Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562
[TBL] [Abstract][Full Text] [Related]
4. Role of FXR in the development of NAFLD and intervention strategies of small molecules.
Long J; Xu Y; Zhang X; Wu B; Wang C
Arch Biochem Biophys; 2024 Jul; 757():110024. PubMed ID: 38703803
[TBL] [Abstract][Full Text] [Related]
5. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
Wang J; Yang N; Xu Y
Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
[TBL] [Abstract][Full Text] [Related]
6. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.
Cheng Z; Chen Y; Schnabl B; Chu H; Yang L
J Adv Res; 2024 May; 59():173-187. PubMed ID: 37356804
[TBL] [Abstract][Full Text] [Related]
7. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
[TBL] [Abstract][Full Text] [Related]
8. Endocrine causes of nonalcoholic fatty liver disease.
Marino L; Jornayvaz FR
World J Gastroenterol; 2015 Oct; 21(39):11053-76. PubMed ID: 26494962
[TBL] [Abstract][Full Text] [Related]
9. Bile acids and sphingolipids in non-alcoholic fatty liver disease.
Jackson KG; Way GW; Zhou H
Chin Med J (Engl); 2022 May; 135(10):1163-1171. PubMed ID: 35788089
[TBL] [Abstract][Full Text] [Related]
10. Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis.
Stine JG; Welles JE; Keating S; Hussaini Z; Soriano C; Heinle JW; Geyer N; Chinchilli VM; Loomba R; Kimball SR
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986211
[TBL] [Abstract][Full Text] [Related]
11. [Advances in traditional Chinese medicine treatment of non-alcoholic fatty liver disease via farnesoid X receptor].
Zhao HH; Cui J; Zhang JJ; Chen JX; Shi AH; Zhu XS
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6582-6591. PubMed ID: 38212018
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease.
Vidal-Cevallos P; Murúa-Beltrán Gall S; Uribe M; Chávez-Tapia NC
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834051
[TBL] [Abstract][Full Text] [Related]
13. Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19.
Bai Y; Zhang J; Li J; Liao M; Zhang Y; Xia Y; Wei Z; Dai Y
Br J Pharmacol; 2024 Jun; ():. PubMed ID: 38839561
[TBL] [Abstract][Full Text] [Related]
14. SIRT6: therapeutic target for nonalcoholic fatty liver disease.
Zang M; Gao B
Trends Endocrinol Metab; 2022 Dec; 33(12):801-803. PubMed ID: 36328906
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Fibroblast Growth Factor-21 Analogs for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.
Jeong C; Han N; Jeon N; Rhee SJ; Staatz CE; Kim MS; Baek IH
Clin Pharmacol Ther; 2024 Jul; 116(1):72-81. PubMed ID: 38666606
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease.
Liu J; Song Y; Wang Y; Hong H
Expert Opin Ther Targets; 2023; 27(11):1145-1157. PubMed ID: 37861098
[TBL] [Abstract][Full Text] [Related]
17. PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD).
Wang JZ; Zhang YH; Bai J; Liu YW; Du WT
Metabol Open; 2019 Sep; 3():100014. PubMed ID: 32812930
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor 19 in Alcohol-Associated Liver Disease: Bile Acids and Dysbiosis and Inflammation, Oh My!
Kennedy L
Cell Mol Gastroenterol Hepatol; 2024; 18(1):159-160. PubMed ID: 38636549
[No Abstract] [Full Text] [Related]
19. Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting.
Li Y; Zheng M; Limbara S; Zhang S; Yu Y; Yu L; Jiao J
J Clin Transl Hepatol; 2024 Apr; 12(4):416-427. PubMed ID: 38638376
[TBL] [Abstract][Full Text] [Related]
20. Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease.
Cho SW
Endocrinol Metab (Seoul); 2024 Apr; 39(2):285-287. PubMed ID: 38693819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
